Information service
07 Natural and applied sciences
New standards
ISO 18744:2016/Amd 1:2026
Microbiology of the food chain — Detection and enumeration of Cryptosporidium and Giardia in fresh leafy green vegetables and berry fruits — Amendment 1: Method validation studies and performance characteristics
Scope: Amendment to ISO 18744:2016
Base documents:
ISO 9491-1:2026
Biotechnology — Predictive computational models in personalized medicine research — Part 1: Constructing, verifying and validating models
Scope: This document specifies requirements and recommendations for the design, development and implementation of predictive computational models for research purposes in the field of personalized medicine and health product development.
This document addresses the set-up, formatting, validation, simulation, storing and sharing of computational models used for personalized medicine. Requirements and recommendations for data used to construct or required for validating such models are also specified. This includes rules for formatting, descriptions, annotations, interoperability, integration, access and provenance of such data.
This document does not apply to computational models used for standard routine clinical, diagnostic or therapeutic purposes.
This document addresses the set-up, formatting, validation, simulation, storing and sharing of computational models used for personalized medicine. Requirements and recommendations for data used to construct or required for validating such models are also specified. This includes rules for formatting, descriptions, annotations, interoperability, integration, access and provenance of such data.
This document does not apply to computational models used for standard routine clinical, diagnostic or therapeutic purposes.
Base documents:
Replaces: ISO/TS 9491-1:2023
ISO 23494-1:2026
Biotechnology — Provenance information model for biological material and data — Part 1: Design concepts and general requirements
Scope: This document specifies a general concept for provenance information of biological material and data, organizational roles, and requirements for provenance information management. The provenance information covers any information relevant to the traceability, quality and fitness for purpose of the biological material and data generated throughout the life cycle of the biological material from collection to analysis, including data originating from analytical procedures applied to the biological material and further processing of the data.
This document is applicable to organizations, authorities and industries that are:
acquiring, collecting, processing, testing, analysing, storing, or distributing biological material in biotechnology and biomedicine (e.g., biobanks, laboratories, biomedical research as well as biotechnological development or production);
generating, collecting, analysing, processing, or storing data on and related to biological material (e.g., biobanks, laboratories, developers, manufacturers, or other institutions and commercial organizations in biotechnology or biomedicine);
generating, collecting, analysing, processing, or storing data or digital objects in biotechnology and biomedicine (e.g., in vitro/in vivo/in silico diagnostics developers and manufacturers, or other institutions and commercial organizations in the domain);
manufacturing devices or software for the aforementioned tasks or providing facilities for these tasks.
This document is also applicable to providers of services related to provenance information management (e.g., provenance information generation, storage, provision, or validation).
This document can be used by customers, regulatory authorities, organizations and schemes using peer-assessment, accreditation bodies, and others for confirming or recognizing the competence of the aforementioned parties.
This document does not apply to biological material and data used for medical diagnosis, treatment and therapy.
NOTE 1 This document can be applied by organizations performing laboratory or research activities as well as other activities in biotechnology and biomedicine.
NOTE 2 International, national, or regional regulations, standards, or requirements can apply to specific topics covered in this document, e.g., for organizations handling human materials procured and used for diagnostic and treatment purposes.
This document is applicable to organizations, authorities and industries that are:
acquiring, collecting, processing, testing, analysing, storing, or distributing biological material in biotechnology and biomedicine (e.g., biobanks, laboratories, biomedical research as well as biotechnological development or production);
generating, collecting, analysing, processing, or storing data on and related to biological material (e.g., biobanks, laboratories, developers, manufacturers, or other institutions and commercial organizations in biotechnology or biomedicine);
generating, collecting, analysing, processing, or storing data or digital objects in biotechnology and biomedicine (e.g., in vitro/in vivo/in silico diagnostics developers and manufacturers, or other institutions and commercial organizations in the domain);
manufacturing devices or software for the aforementioned tasks or providing facilities for these tasks.
This document is also applicable to providers of services related to provenance information management (e.g., provenance information generation, storage, provision, or validation).
This document can be used by customers, regulatory authorities, organizations and schemes using peer-assessment, accreditation bodies, and others for confirming or recognizing the competence of the aforementioned parties.
This document does not apply to biological material and data used for medical diagnosis, treatment and therapy.
NOTE 1 This document can be applied by organizations performing laboratory or research activities as well as other activities in biotechnology and biomedicine.
NOTE 2 International, national, or regional regulations, standards, or requirements can apply to specific topics covered in this document, e.g., for organizations handling human materials procured and used for diagnostic and treatment purposes.
Base documents:
Replaces: ISO/TS 23494-1:2023
ISO 23494-2:2026
Biotechnology — Provenance information model for biological material and data — Part 2: Common provenance model
Scope: This document specifies a common model for generating, maintaining, and provisioning provenance information on objects, such as biological material and data. This document also specifies requirements for provenance information serialization to achieve its interoperability. The provenance information covers any information relevant to the traceability, quality and fitness for purpose of the biological material and data generated throughout the life cycle of the biological material from collection to analysis, including data originating from analytical procedures applied to the biological material and further processing of the data.
This document is applicable to organizations, authorities and industries that are:
acquiring, collecting, processing, testing, analysing, storing, or distributing biological material in biotechnology and biomedicine (e.g., biobanks, laboratories, biomedical research as well as biotechnological development or production);
generating, collecting, analysing, processing, or storing data on and related to biological material (e.g., biobanks, laboratories, developers, manufacturers, or other institutions and commercial organizations in biotechnology or biomedicine);
generating, collecting, analysing, processing, or storing data or digital objects in biotechnology and biomedicine (e.g., in vitro/in vivo/in silico diagnostics developers and manufacturers, or other institutions and commercial organizations in the domain);
)manufacturing devices or software for the afore mentioned tasks or providing facilities for these tasks.
This document is also applicable to providers of services related to provenance information management (e.g., provenance information generation, storage, provision, or validation).
Customers, regulatory authorities, organizations and schemes using peer-assessment, accreditation bodies, and others can use this document in confirming or recognizing the competence of the aforementioned parties.
This document does not apply to biological material and data used for medical diagnosis and therapy.
NOTE 1 This document can be applied by organizations performing laboratory or research activities as well as other activities in biotechnology and biomedicine.
NOTE 2 International, national, or regional regulations, standards, or requirements can apply to specific topics covered in this document, e.g., for organizations handling human materials procured and used for diagnostic and treatment purposes.
This document is applicable to organizations, authorities and industries that are:
acquiring, collecting, processing, testing, analysing, storing, or distributing biological material in biotechnology and biomedicine (e.g., biobanks, laboratories, biomedical research as well as biotechnological development or production);
generating, collecting, analysing, processing, or storing data on and related to biological material (e.g., biobanks, laboratories, developers, manufacturers, or other institutions and commercial organizations in biotechnology or biomedicine);
generating, collecting, analysing, processing, or storing data or digital objects in biotechnology and biomedicine (e.g., in vitro/in vivo/in silico diagnostics developers and manufacturers, or other institutions and commercial organizations in the domain);
)manufacturing devices or software for the afore mentioned tasks or providing facilities for these tasks.
This document is also applicable to providers of services related to provenance information management (e.g., provenance information generation, storage, provision, or validation).
Customers, regulatory authorities, organizations and schemes using peer-assessment, accreditation bodies, and others can use this document in confirming or recognizing the competence of the aforementioned parties.
This document does not apply to biological material and data used for medical diagnosis and therapy.
NOTE 1 This document can be applied by organizations performing laboratory or research activities as well as other activities in biotechnology and biomedicine.
NOTE 2 International, national, or regional regulations, standards, or requirements can apply to specific topics covered in this document, e.g., for organizations handling human materials procured and used for diagnostic and treatment purposes.
Base documents:
IEC TS 62565-4-3:2026
Nanomanufacturing - Product specification - Part 4-3: Nanophotonic products - Blank detail specification: quantum dot enabled light emitting diodes
Scope: IEC TS 62565-4-3:2026, which is a Technical Specification, establishes a blank detail specification (BDS) for quantum dot enabled light emitting diodes (QLEDs) used for printed light emitting diodes (LEDs).
This document is intended to be used for display applications.
The relevant key control characteristics (KCCs) include optical, physical, chemical, and structural properties of colloidal quantum dots (QDs). For each KCC listed, methods and existing standards for their measurement are reported. The applicability of such methods and standards to different material categories (physical forms) of QDs, for example colloidal solution, inks, films, is indicated.
Numeric values for the KCCs are left blank as they will be specified between customer and supplier in the detail specification (DS). In the DS, KCCs can be added or removed if agreed between customer and supplier.
This document is intended to be used for display applications.
The relevant key control characteristics (KCCs) include optical, physical, chemical, and structural properties of colloidal quantum dots (QDs). For each KCC listed, methods and existing standards for their measurement are reported. The applicability of such methods and standards to different material categories (physical forms) of QDs, for example colloidal solution, inks, films, is indicated.
Numeric values for the KCCs are left blank as they will be specified between customer and supplier in the detail specification (DS). In the DS, KCCs can be added or removed if agreed between customer and supplier.
Base documents:
IEC TS 62607-6-36:2026
<p>Nanomanufacturing - Key control characteristics - Part 6-36: Graphene-related products - Reduction status of graphene oxide and reduced graphene oxide: UV-Vis absorption spectroscopy</p>
Scope: IEC TS 62607-6-36:2026, which is a Technical Specification, establishes a standardized method to determine the key control characteristic
• reduction status
for graphene oxide (GO) and reduced graphene oxide (rGO) by
• ultraviolet-visible spectroscopy (UV-Vis).
The reduction status is not a quantitative value, but rather a compilation (table) of six parameters extracted from UV-Vis absorption spectra. These six parameters can be obtained from GO and rGO as follows:
(1) the peak location of GO, (2) the shoulder peak of GO, (3) the full width at half maximum (FWHM) of the main absorption peak of GO, (4) the peak location of rGO, (5) FWHM of the main absorption peak of rGO and (6) the spectral peak shifts between GO and rGO.
• The method is applicable to the characterization of GO and rGO materials (where rGO is obtained from the corresponding GO) produced by different reduction techniques, as well as to commercial products in solution or film form.
• Individual GO or rGO materials can also be characterized, but only partial parameters can be obtained. Specifically, peak location, FWHM, and shoulder peak can be measured from each GO or rGO material, while peak shift requires both GO and its corresponding rGO for comparison.
• The method is suitable for quality assurance and for monitoring the reduction process during the production of rGO.
• The method does not provide full chemical analysis. Complementary techniques can be required beyond the UV-Vis spectral features.
• reduction status
for graphene oxide (GO) and reduced graphene oxide (rGO) by
• ultraviolet-visible spectroscopy (UV-Vis).
The reduction status is not a quantitative value, but rather a compilation (table) of six parameters extracted from UV-Vis absorption spectra. These six parameters can be obtained from GO and rGO as follows:
(1) the peak location of GO, (2) the shoulder peak of GO, (3) the full width at half maximum (FWHM) of the main absorption peak of GO, (4) the peak location of rGO, (5) FWHM of the main absorption peak of rGO and (6) the spectral peak shifts between GO and rGO.
• The method is applicable to the characterization of GO and rGO materials (where rGO is obtained from the corresponding GO) produced by different reduction techniques, as well as to commercial products in solution or film form.
• Individual GO or rGO materials can also be characterized, but only partial parameters can be obtained. Specifically, peak location, FWHM, and shoulder peak can be measured from each GO or rGO material, while peak shift requires both GO and its corresponding rGO for comparison.
• The method is suitable for quality assurance and for monitoring the reduction process during the production of rGO.
• The method does not provide full chemical analysis. Complementary techniques can be required beyond the UV-Vis spectral features.
Base documents:
Replaced standards
ISO/TS 23494-1:2023
Biotechnology — Provenance information model for biological material and data — Part 1: Design concepts and general requirements
Scope: This document specifies a general concept for a provenance information model for biological material and data and requirements for provenance data interoperability and serialization.
The provenance information model covers any information relevant to the quality and fitness for purpose of the biological material generated throughout the preanalytical phase of the materials life cycle from collection to analysis, data originating from analytical procedures applied to the biological material and results from further mathematical processing of the data.
This document is applicable to organizations, authorities and industries that are:
a) collecting, processing or distributing biological material for research;
b) generating, collecting, analysing or storing data on biological material.
This document does not apply to biological material and data used for other than research or in fields that are regulated by national, regional or international laws, such as medical diagnosis and therapy or food production.
NOTE International, national, or regional regulations or requirements can also apply to specific topics covered in this document.
The provenance information model covers any information relevant to the quality and fitness for purpose of the biological material generated throughout the preanalytical phase of the materials life cycle from collection to analysis, data originating from analytical procedures applied to the biological material and results from further mathematical processing of the data.
This document is applicable to organizations, authorities and industries that are:
a) collecting, processing or distributing biological material for research;
b) generating, collecting, analysing or storing data on biological material.
This document does not apply to biological material and data used for other than research or in fields that are regulated by national, regional or international laws, such as medical diagnosis and therapy or food production.
NOTE International, national, or regional regulations or requirements can also apply to specific topics covered in this document.
Base documents:
Replaced: ISO 23494-1:2026
ISO/TS 9491-1:2023
Biotechnology — Predictive computational models in personalized medicine research — Part 1: Constructing, verifying and validating models
Scope: This document specifies requirements and recommendations for the design, development and establishment of predictive computational models for research purposes in the field of personalized medicine. It addresses the set-up, formatting, validation, simulation, storing and sharing of computational models used for personalized medicine. Requirements and recommendations for data used to construct or required for validating such models are also addressed. This includes rules for formatting, descriptions, annotations, interoperability, integration, access and provenance of such data.
This document does not apply to computational models used for clinical, diagnostic or therapeutic purposes.
This document does not apply to computational models used for clinical, diagnostic or therapeutic purposes.
Base documents:
Replaced: ISO 9491-1:2026